流感疫苗接种对心力衰竭患者的影响:系统性审查和元分析
Nicole Ivars-Obermeier1, Pere Llorens1, Xavier Castells2
1Emergency Department, Short Stay Unit and Hospitalization at Home Unit, Hospital General Universitario Dr. Balmis de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Universidad Miguel Hernández, Alicante, Spain.
European journal of heart failure
|March 2, 2026
概括
在急性心力衰竭 (AHF) 患者中接种流感疫苗与降低死亡率有关. 这项对观察性研究的元分析发现,在AHF患者中,接种疫苗与较低的短期和长期全因死亡率有关.
科学领域:
- 心脏病学 心脏病学
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
背景情况:
- 众所周知,接种流感疫苗可以预防心力衰竭 (HF) 患者的心脏衰竭.
- 关于流感疫苗在急性心力衰竭 (AHF) 脱补偿发作期间的影响的证据有限.
研究的目的:
- 系统地审查和元分析流感疫苗接种对被诊断为AHF的患者全因死亡率的影响.
主要方法:
- 我们对PubMed,Medline,Cochrane控制试验中央注册表和Cochrane系统审查数据库进行了系统的搜索.
- 包括长度研究,比较接种疫苗和未接种疫苗的AHF患者.
- 主要结局是1年全因死亡率;聚合分析使用随机效应模型进行敏感性分析.
主要成果:
- 分析了五项观察性队列研究,显示了较低的统计异质性 (I2 = 33.7%).
- 对混调整数据的聚合分析显示,接种疫苗的AHF患者的1年全因死亡率降低 (HR 0.89,95% CI 0.83-0.96).
- 还观察到住院和90天死亡率的减少 (aOR 0.85,95% CI 0.70-1.01;aHR 0.86,95% CI 0.76-0.96).
结论:
- 流感疫苗接种与不补偿性HF患者的短期和长期全因死亡率降低有关.
- 鉴于包含的研究的观察性质,结果可能会受到残留混的影响,并且无法最终推断因果关系.
更多相关视频
相关概念视频
01:27Heart Failure I: Introduction
1.7K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.7K
01:29Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
01:26Heart Failure III: Clinical Manifestations
1.2K
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
1.2K
01:30Heart Failure IV: Classification and Diagnostic Evaluation
1.0K
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
1.0K
01:30Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
01:22Heart Failure VI: Adjunct Therapies
632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632